Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUVQFW)

• Drug Name: CT301 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID: TTD Drug ID: DMUVQFW

Molecule-Related Drug Atlas

Drug(s) Targeting Integrin alpha-4 (ITGA4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vedolizmab	DMV3YMX	Crohn disease	DD70	Approved	[2]
Antegren	DMNC64R	Multiple sclerosis	8A40	Approved	[3]
Natalizumab	DMAK85L	Crohn disease	DD70	Approved	[4]
PB006	DMVHGLA	Crohn disease	DD70	Phase 3	[5]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[6]
AMG-181	DMODJTX	Crohn disease	DD70	Phase 2	[7]
Senktide	DMOH8LD	Epilepsy	8A60-8A68	Phase 2	[8]
BIO-1211	DMKICA3	Asthma	CA23	Phase 2	[9]
PTG-100	DMQNRGE	Ulcerative colitis	DD71	Phase 1	[7]
ELND-002	DMM9S51	Autoimmune diabetes	5A10	Phase 1	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Integrin alpha-4 (ITGA4)	TT4BT06	ITA4_HUMAN	Antagonist	[1]

References

• [1] Prolonged reversal of chronic experimental allergic encephalomyelitis using a small molecule inhibitor of alpha4 integrin. J Neuroimmunol. 2002 Oct;131(1-2):147-59.
• [2] Clinical pipeline report, company report or official report of Takeda (2009).
• [3] Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curr Opin Chem Biol. 1998 Aug;2(4):453-7.
• [4] Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring. Front Immunol. 2020 Sep 24;11:549842.
• [5] Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial. JAMA Neurol. 2023 Mar 1;80(3):298-307.
• [6] Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] A small-molecule, tight-binding inhibitor of the integrin alpha(4)beta(1) blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):603-11.
• [10] Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol. 2003 Jun 15;170(12):5912-8.